ALISO VIEJO, Calif.
- Aug. 21, 2019
-- Human insulin (HI) is synthetic insulin, which mimics the effects and functionality of natural insulin in humans. It is generally created by growing the insulin protein in the E. coli bacteria.
In a recent P&S Intelligence research, the human insulin market
market) is segmented by type, application, and region. Under the product segment, the market is further divided into HI drugs and delivery devices. Due to increase in research and development activities for drugs discovery and manufacture, and high prevalence of diabetes, HI drugs held the larger share (79.5%) in the market in 2017 in terms of value. Furthermore, the rise in geriatric population and growth in demand for HI analogs is also pushing the market progress; analogs and biologics are two categories of the HI drugs division.
Looking at the market growth, the human insulin market
players, in order to increase their profits, are joining hands with one another through partnerships and collaborations. For instance, in August 2018, Ypsomed AG entered into a partnership with JRDF. Under the terms of the agreement, JRDF will contribute financial resources to help Ypsomed AG ramp up the development of its next-generation, fully-interoperable myLife YpsoPump. Similarly, in October 2018, Koninklijke Philips N.V. (Philips) collaborated with Ypsomed AG to develop digital monitoring services for self-medication adherence, based on Philips' HealthSuite digital platform and Ypsomed's connected devices.